For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur® Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver Commitment to sustainability demonstrated by SBTi approval of our targets to … [Read more…]
